Oramed Pharmaceuticals, Inc., founded in 2006 and headquartered in Jerusalem, is a biotech company specializing in the development of oral drug delivery systems. Their flagship product is an oral insulin capsule aimed at treating type 2 diabetes. The company also focuses on creating delivery solutions for other drugs and vaccines, striving to revolutionize the way medications are administered and improving patient compliance and outcomes.
Oramed has achieved significant milestones, including being publicly traded on Nasdaq (ORMP) and the Tel Aviv Stock Exchange (ORMP). The company is a component of the Russell Microcap Index. Notable achievements include a joint venture with HTIT to advance oral drug delivery technology globally and a distribution contract with Medicox for South Korea. CEO Nadav Kidron leads the company, which continues to make strides in the biotech industry.
